Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Pliant Therapeutics (PLRX) Invested Capital (2019 - 2026)

Pliant Therapeutics has reported Invested Capital over the past 8 years, most recently at $165.2 million for Q1 2026.

  • Quarterly Invested Capital fell 42.54% to $165.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $165.2 million through Mar 2026, down 42.54% year-over-year, with the annual reading at $181.2 million for FY2025, 45.79% down from the prior year.
  • Invested Capital was $165.2 million for Q1 2026 at Pliant Therapeutics, down from $181.2 million in the prior quarter.
  • Over five years, Invested Capital peaked at $571.9 million in Q1 2023 and troughed at $157.7 million in Q2 2022.
  • The 5-year median for Invested Capital is $334.3 million (2024), against an average of $342.9 million.
  • Year-over-year, Invested Capital soared 244.45% in 2023 and then crashed 45.79% in 2025.
  • A 5-year view of Invested Capital shows it stood at $323.3 million in 2022, then soared by 49.61% to $483.6 million in 2023, then crashed by 30.88% to $334.3 million in 2024, then crashed by 45.79% to $181.2 million in 2025, then fell by 8.85% to $165.2 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Invested Capital are $165.2 million (Q1 2026), $181.2 million (Q4 2025), and $230.7 million (Q3 2025).